Effect of L-carnitine administration on erythrocyte survival in haemodialysis patients [7]

Nephrology Dialysis Transplantation

Volumn 21, Issue 9, 2006, Pages 2671-2672

  Arduini, Arduino ^a   Bonomini, Mario ^b   Clutterbuck, Elaine J ^c   Laffan, Michael A ^c   Pusey, Charles D ^c  

^a Iperboreal Pharma Srl   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE; FERRITIN; IRON SACCHARATE; PLACEBO; RECOMBINANT ERYTHROPOIETIN; SODIUM CHLORIDE; VITAMIN B COMPLEX;

ANEMIA; BLOOD AUTOTRANSFUSION; BLOOD SAMPLING; CARNITINE DEFICIENCY; CELL LABELING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; ERYTHROCYTE LIFESPAN; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; HEMATOCRIT; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; KIDNEY FAILURE; LETTER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; BLOOD; CELL SURVIVAL; COMPARATIVE STUDY; DRUG EFFECT; ERYTHROCYTE; FOLLOW UP; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME; UREMIA;

ANEMIA; CARNITINE; CELL SURVIVAL; ERYTHROCYTES; FOLLOW-UP STUDIES; HEMATOCRIT; HUMANS; RANDOMIZED CONTROLLED TRIALS; RENAL DIALYSIS; TREATMENT OUTCOME; UREMIA; VITAMIN B COMPLEX;

EID: 33750116191     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl155     Document Type: Letter

References (10)

1. Hurot JM, Cucherat M, Haugh M, Fouque D. Effects of L-carnitine supplementation in maintenance hemodialysis patients: A systematic review. J Am Soc Nephrol 2002; 13: 708-714
2. Heaton WA. Evaluation of posttransfusion recovery and survival of trasfuded RBCs. Transfus Med Rev 1992; 6: 153-169
3. Mohandas N, Chasis JA. Red blood cell deformability, membrane material properties and shape: Regulation by transmembrane, skeletal and cytosolic proteins and lipids. Semin Hematol 1993; 30: 171-192
4. Linde T, Sandhagen B, Wikstrom B, Danielson BG. The required dose of erythropoietin during renal anaemia treatment is related to the degree of impairment in erythrocyte deformability. Nephrol Dial Transplant 1997; 12: 2375-2379
5. Rosenmund A, Binswanger U, Straub PW. Oxidative injury to erythrocytes, cell rigidity, and splenic hemolysis in hemodialyzed uremic patients. Ann Intern Med 1975; 82: 460-465
6. Matsumura M, Hatakeyama S, Koni I, Mabuchi H, Muramoto H. Correlation between serum carnitine levels and erythrocyte osmotic fragility in hemodialysis patients. Nephron 1996; 72: 574-578
7. Arduini A, Rossi M, Mancinelli G et al. Effect of L-carnitine and acetyl-L-carnitine on the human erythrocyte membrane stability and deformability. Life Sci 1990; 47: 2395-2400
8. Kadiroglu AK, Yilmaz ME, Sit D, Kara IH, Isikoglu B. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in haemodialysis patients. Renal Fail 2005; 27: 367-372
9. Arduini A, Holme S, Sweeney JD, Dottori S, Sciarroni AF, Calvani M. Addition of L-carnitine to additive solution-suspended red cells stored at 4 degrees C reduces in vitro hemolysis and improves in vivo viability. Transfusion 1997; 37: 166-174
10. de los Reyes B, Navarro JA, Perez-Garcia R et al. Effects of L-carnitine on erythrocyte acyl-CoA, free CoA, and glycerophospholipid acyltransferase in uremia. Am J Clin Nutr 1998; 67: 386-390